A. Covelli

673 total citations
23 papers, 447 citations indexed

About

A. Covelli is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, A. Covelli has authored 23 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in A. Covelli's work include Acute Myeloid Leukemia Research (5 papers), Drug Transport and Resistance Mechanisms (5 papers) and Acute Lymphoblastic Leukemia research (3 papers). A. Covelli is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Drug Transport and Resistance Mechanisms (5 papers) and Acute Lymphoblastic Leukemia research (3 papers). A. Covelli collaborates with scholars based in Italy, Switzerland and Germany. A. Covelli's co-authors include Franco Mandelli, Britt Sundman‐Engberg, C Peschle, Lars Möllgård, Dawei Xu, Astrid Gruber, Sergio Ottolenghi, Paola Comi, E. Polli and Christer Paul and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

A. Covelli

20 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Covelli Italy 11 174 158 134 95 67 23 447
Marie Loosveld France 14 133 0.8× 199 1.3× 194 1.4× 77 0.8× 44 0.7× 46 753
Lidija Dokmanović Serbia 13 88 0.5× 145 0.9× 114 0.9× 61 0.6× 109 1.6× 47 419
Fabio Timeus Italy 15 106 0.6× 266 1.7× 212 1.6× 122 1.3× 28 0.4× 48 663
Nicoletta Crescenzio Italy 16 124 0.7× 245 1.6× 197 1.5× 87 0.9× 31 0.5× 33 663
Jean Pierre Marie France 11 113 0.6× 130 0.8× 186 1.4× 56 0.6× 48 0.7× 19 405
Juan Eduardo Megías‐Vericat Spain 16 164 0.9× 230 1.5× 359 2.7× 100 1.1× 49 0.7× 57 654
Yasukazu Kawai Japan 11 78 0.4× 253 1.6× 194 1.4× 59 0.6× 23 0.3× 38 487
Lisa Gallinaro Italy 16 84 0.5× 306 1.9× 396 3.0× 84 0.9× 51 0.8× 32 856
Eiju Negoro Japan 11 79 0.5× 136 0.9× 107 0.8× 40 0.4× 15 0.2× 39 318
Anna Szmigielska‐Kapłon Poland 16 151 0.9× 198 1.3× 215 1.6× 187 2.0× 25 0.4× 55 570

Countries citing papers authored by A. Covelli

Since Specialization
Citations

This map shows the geographic impact of A. Covelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Covelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Covelli more than expected).

Fields of papers citing papers by A. Covelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Covelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Covelli. The network helps show where A. Covelli may publish in the future.

Co-authorship network of co-authors of A. Covelli

This figure shows the co-authorship network connecting the top 25 collaborators of A. Covelli. A scholar is included among the top collaborators of A. Covelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Covelli. A. Covelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spiliopoulou, Pavlina, Stephen B. Strum, Alexandra Easson, et al.. (2024). 226TiP CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma. Annals of Oncology. 35. S306–S306. 1 indexed citations
2.
Covelli, A., Giuseppe Migliara, Corrado De Vito, et al.. (2024). Fighting HAIs by monitoring hand hygiene compliance in the Umberto I teaching Hospital in Rome. European Journal of Public Health. 34(Supplement_3).
3.
Curigliano, Giuseppe, Carmen Belli, Ilaria Colombo, et al.. (2024). 26O Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors. ESMO Open. 9. 102354–102354.
4.
Mach, Nicolas, Carmen Belli, Eduardo Fernández, et al.. (2023). 1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors. Annals of Oncology. 34. S629–S630. 2 indexed citations
5.
Flatz, Lukas, Nikolaus B. Wagner, Emanuele Puca, et al.. (2023). 1138P Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity. Annals of Oncology. 34. S682–S682. 1 indexed citations
7.
Tesi, Bianca, et al.. (2023). “Health is a serious game”: Gamification as a tool for primary prevention in Public Health. European Journal of Public Health. 33(Supplement_2).
8.
Kulandavelu, Shathiyah, Nana Sunn, Jun Mu, et al.. (2006). Embryonic and Neonatal Phenotyping of Genetically Engineered Mice. ILAR Journal. 47(2). 103–117. 59 indexed citations
9.
Visani, Giuseppe, D W Milligan, Fabiana Leoni, et al.. (2001). Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia. 15(5). 764–771. 25 indexed citations
10.
Tidefelt, Ulf, Jan Liliemark, Astrid Gruber, et al.. (2000). P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia. Journal of Clinical Oncology. 18(9). 1837–1844. 80 indexed citations
11.
Advani, Ranjana H., Giuseppe Visani, D Milligan, et al.. (1999). Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC). Advances in experimental medicine and biology. 457. 47–56. 33 indexed citations
12.
Covelli, A.. (1999). Modulation of multidrug resistance (MDR) in hematological malignancies. Annals of Oncology. 10. S53–S60. 43 indexed citations
13.
Covelli, A.. (1998). [SDZ PSC 833: a novel modulator of MDR].. PubMed. 83(5 Suppl). S21–4. 6 indexed citations
14.
Fabritiis, Paolo de, A. Covelli, F. Simone, et al.. (1989). In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine. Experimental and Molecular Pathology. 50(2). 210–219. 7 indexed citations
15.
Petti, Maria Concetta, Franco Mandelli, Giuseppe Avvisati, et al.. (1989). High‐dose ARA‐C (HiDAC) plus asparaginase in elderly patients with acute non‐lymphocytic leukemia: A pilot multicentric study by the Italian cooperative group GIMEMA. European Journal Of Haematology. 42(1). 24–31. 15 indexed citations
16.
Mandelli, Franco, A. Covelli, Matteo Luciani, et al.. (1989). Chronic lymphocytic leukemia (CLL) in younger adults: A retrospective study of 133 cases. Hematological Oncology. 7(2). 127–137. 19 indexed citations
17.
Coppola, Giuseppe, et al.. (1988). Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.. PubMed. 1(2). 93–9. 7 indexed citations
18.
Amadori, Sergio, Adriana Ceci, A Comelli, et al.. (1987). Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.. Journal of Clinical Oncology. 5(9). 1356–1363. 38 indexed citations
19.
Perez, G., Biagio Ungaro, A. Covelli, et al.. (1980). Altered Glucoregulatory Response to Physiological Infusions of Epinephrine and Glucagon in Hyperthyroidism*. The Journal of Clinical Endocrinology & Metabolism. 51(5). 972–977. 36 indexed citations
20.
Peschle, C, Giovanni Migliaccio, A. Covelli, et al.. (1980). Hemoglobin synthesis in individual bursts from normal adult blood: all bursts and subcolonies synthesize G gamma-and A gamma-globin chains. Blood. 56(2). 218–226. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026